John Arcaroli, PhD

Publications

• Arcaroli J, Touban B, Tan AC, Garcia M, Powell RW, Eckhardt SG, Elvin P, Messersmith WM. Gene Array and FISH Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer. Clin Cancer Res. 2010 Aug 15;16(16):4165-77. PMID: 20682712
• Tentler J, Nallapareddy S, Tan AC, Spreafico A, Pitts T, Morelli M, Selby H, Kachaeva M, Flanigan S, Kulikowski G, Leong S, Arcaroli J, Messersmith W, Eckhardt SG. Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in KRAS-Mutated Colorectal Cancer. Mol Cancer Ther. 2010 Oct 5. PMID: 20923857
• R. Powell, W. Messersmith, M. Varella-Garcia, A.Tan, B. Touban, T.M. Pitts, A. Dasari, J. Arcaroli. The Combination of PF-03084014 (a ?-secretase inhibitor) and Irinotecan Reduces ALDH+ Tumor-Initiating Cells and Recurrence in Tumors with Elevated Notch Pathway. AACR. Colorectal Cancer: Biology to Treatment. 2010.
• Biomarkers of sensitivity to PF-03084014, a gamma-secretase Inhibitor, in a preclinical model of colorectal cancer
• Biomarkers of sensitivity to RO4929097, a gamma-secretase Inhibitor, in a preclinical model of pancreatic cancer
• Association between IL-32 genotypes and outcome in infection-associated acute lung injury John J Arcaroli, Nianjun Liu, Nengjun Yi, and Edward Abraham Crit Care. 2011; 15(3): R138.
• Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG. Clin Cancer Res. 2012 Feb 15;18(4):1051-62. Epub 2011 Dec 15.
• Similarity-based multi-marker association tests for continuous traits Wan-Yu Lin, Hemant K. Tiwari, Guimin Gao, Kui Zhang, John J Arcaroli, Edward Abraham, Nianjun Liu. Annals of Human Genetics. Accepted.
• Gamma-secretase inhibitors in solid tumor malignancies Arcaroli, J.J., Dasari, A., Messersmith, W.A., Jimeno, A. Drugs Fut 2011, 36(9): 677
• Common PIK3CA mutants and a novel 3’ UTR mutation are associated with increased sensitivity to saracatinib. John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhart, Wells A. Messersmith Clinical Cancer Research-pending
• Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster N, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith W. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Medicine 2012; 1(2): 207–2172.
• Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal Cell-Derived Factor 1a Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer. Neoplasia. 2012, Aug; 14(8): 690-701.
• Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2012 May 22.
• Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res. 2012 May 1;18(9):2704-14.
• Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH(+) tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a ?-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol. 2012 Jun;6(3):370- 81.
• Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli J, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50.
• Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res. 2012 Feb 15;18(4):1051-62.
• Lin WY, Tiwari HK, Gao G, Zhang K, Arcaroli JJ, Abraham E, Liu N. Similarity-based multimarker association tests for continuous traits. Ann Hum Genet. 2012 May;76(3):246- 60.
• Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a ?-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer. 2013 Aug 6;109(3):667-75. PubMed PMID: 23868008
• Avasarala S, Van Scoyk M, Wang J, Sechler M, Vandervest K, Brzezinski C, Weekes C, Edwards MG, Arcaroli J, Davis RE, Bikkavilli RK, Winn RA. hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression. Biol Open. 2013 Jul 15;2(7):675-85. PubMed PMID: 23862015
• Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013 Aug 1;19(15):4149-62. PubMed PMID: 23757356
• Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug;7(4):776-90. PubMed PMID: 23607916
• Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013;4:35. PubMed PMID: 23543898
• Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS One. 2014;9(11):e113037. PubMed PMID: 25401499
• Li L, Abraham AD, Zhou Q, Ali H, O'Brien JV, Hamill BD, Arcaroli JJ, Messersmith WA, LaBarbera DV. An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIa and potent anticancer agent. Mar Drugs. 2014 Sep 19;12(9):4833-50. PubMed PMID: 25244109
• De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs. 2014 Aug;32(4):739-45. PubMed PMID: 24668033
• Bikkavilli RK, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W, Edwards MG, Rathinam MK, Zhou T, Tauler J, Borowicz S, Lussier YA, Parr BA, Cool CD, Winn RA. Wnt7a is a novel inducer of ß-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene. 2015 Oct 16;34(42):5406. PubMed PMID: 26473947
• Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget. 2015 Oct 27;6(33):34561-72. PubMed PMID: 26439693
• Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH. Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist. 2015 Oct;20(10):1189-98. PubMed PMID: 26306903
• Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Front Pharmacol. 2015;6:120. PubMed PMID: 26136684
• Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. ALDH1B1 Is Crucial for Colon Tumorigenesis by Modulating Wnt/ß-Catenin, Notch and PI3K/Akt Signaling Pathways. PLoS One. 2015;10(5):e0121648. PubMed PMID: 25950950
• Bikkavilli RK, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W, Edwards MG, Rathinam MK, Zhou T, Tauler J, Borowicz S, Lussier YA, Parr BA, Cool CD, Winn RA. Wnt7a is a novel inducer of ß-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene. 2015 Oct 16;34(42):5317-28. PubMed PMID: 25728679
• Singh S, Arcaroli J, Thompson DC, Messersmith W, Vasiliou V. Acetaldehyde and retinaldehyde-metabolizing enzymes in colon and pancreatic cancers. Adv Exp Med Biol. 2015;815:281-94. PubMed PMID: 25427913
• Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15;136(8):1967-75. PubMed PMID: 25242168